miR-4700-3p sensitized MDR cells to chemotherapy, and FOXC2 was validated as its functional target, which may provide a promising method to antagonize the elevated FENDRR/FOXC2 axis in GC MDR. Here, FOXC2 is linked to gastric cancer.